コンテンツへスキップ
Merck
  • Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.

Blood-brain barrier pharmacoproteomics-based reconstruction of the in vivo brain distribution of P-glycoprotein substrates in cynomolgus monkeys.

The Journal of pharmacology and experimental therapeutics (2014-06-21)
Yasuo Uchida, Kentaro Wakayama, Sumio Ohtsuki, Masato Chiba, Tomoyuki Ohe, Yasuyuki Ishii, Tetsuya Terasaki
要旨

The aim of this study was to investigate whether in vivo drug distribution in brain in monkeys can be reconstructed by integrating four factors: protein expression levels of P-glycoprotein (P-gp)/multidrug resistance protein 1 at the blood-brain barrier (BBB), in vitro transport activity per P-gp molecule, and unbound drug fractions in plasma and brain. For five P-gp substrates (indinavir, quinidine, loperamide, paclitaxel, and verapamil) and one nonsubstrate (diazepam), in vitro P-gp transport activities were determined by measuring transcellular transport across monolayers of cynomolgus monkey P-gp-transfected LLC-PK1 and parental cells. In vivo P-gp functions at the BBB were reconstructed from in vitro P-gp transport activities and P-gp expression levels in transfected cells and cynomolgus brain microvessels. Brain-to-plasma concentration ratios (Kp,brain) were reconstructed by integrating the reconstructed in vivo P-gp functions with drug unbound fractions in plasma and brain. For all compounds, the reconstructed Kp,brain values were within a 3-fold range of observed values, as determined by constant intravenous infusion in adult cynomolgus monkeys. Among four factors, plasma unbound fraction was the most sensitive factor to species differences in Kp,brain between monkeys and mice. Unbound brain-to-plasma concentration ratios (Kp,uu,brain) were reconstructed as the reciprocal of the reconstructed in vivo P-gp functions, and the reconstructed Kp,uu,brain values were within a 3-fold range of in vivo values, which were estimated from observed Kp,brain and unbound fractions. This study experimentally demonstrates that brain distributions of P-gp substrates and nonsubstrate can be reconstructed on the basis of pharmacoproteomic concept in monkeys, which serve as a robust model of drug distribution in human brain.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
(±)-ベラパミル 塩酸塩, ≥99% (titration), powder
Supelco
ジアゼパム 溶液, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
ジアゼパム
USP
ロペラミド 塩酸塩, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ロペラミド 塩酸塩
Sigma-Aldrich
キニジン, anhydrous
USP
ベラパミル 塩酸塩, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
キニジン, crystallized, ≥98.0% (dried material, NT)
Supelco
ロペラミド 塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
(±)-ベラパミル 塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
(±)-ベラパミル 塩酸塩, European Pharmacopoeia (EP) Reference Standard
ジアゼパム, European Pharmacopoeia (EP) Reference Standard
Supelco
ロペラミド 塩酸塩, VETRANAL®, analytical standard
ロペラミド 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Indinavir, European Pharmacopoeia (EP) Reference Standard